A detailed history of Abingworth LLP transactions in Nu Cana PLC stock. As of the latest transaction made, Abingworth LLP holds 3,333,333 shares of NCNA stock, worth $4.1 Million. This represents 0.73% of its overall portfolio holdings.

Number of Shares
3,333,333
Previous 3,333,333 -0.0%
Holding current value
$4.1 Million
Previous $3.4 Million 35.32%
% of portfolio
0.73%
Previous 1.16%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 16, 2020

BUY
$4.57 - $6.48 $15.2 Million - $21.6 Million
3,333,333 New
3,333,333 $17.2 Million

Others Institutions Holding NCNA

# of Institutions
1
Shares Held
3.33M
Call Options Held
0
Put Options Held
0

About NuCana plc


  • Ticker NCNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,196,000
  • Market Cap $64.2M
  • Description
  • NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...
More about NCNA
Track This Portfolio

Track Abingworth LLP Portfolio

Follow Abingworth LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abingworth LLP, based on Form 13F filings with the SEC.

News

Stay updated on Abingworth LLP with notifications on news.